Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Arrakis Therapeutics

http://arrakistx.com/

Latest From Arrakis Therapeutics

Canaan Has Capital For Start-Ups With Eye On New Twists On Traditional Modalities In Pharma

VC partner Colleen Cuffaro talked to Scrip about how the investment firm plans to direct investment in biopharma and raising capital in a challenging environment.

Financing StartUps and SMEs

Roche Partnering Finds Upfront Fee Relief In Current Market

Barbara Lueckel, head of research technologies partnering, said Roche’s approach to platform deals has evolved with a focus on “generational technologies” to answer tough scientific questions. 

Deals Innovation

Amgen, J&J, Takeda R&D Heads On The Era Of Human Data, Treating Disease Earlier

Big pharma R&D leaders discuss the confluence of technology and biotech driving insights into biology and how industry is doing in terms of identifying patients earlier in disease.

Research & Development Artificial Intelligence

Big Pharma Deal Hunters Target RNA Approaches In Race To Build Best Platforms

The potential for RNA medicines to achieve holy grail goals – reaching undruggable targets and bringing drugs to market faster – has Pfizer, Lilly, Novartis and others in a deal-making frame of mind. 

Deals Innovation
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Drug Discovery Tools
UsernamePublicRestriction

Register